{"nctId":"NCT00405704","briefTitle":"Randomized Intervention for Children With Vesicoureteral Reflux (RIVUR)","startDateStruct":{"date":"2007-05","type":"ACTUAL"},"conditions":["Vesicoureteral Reflux","Urinary Tract Infections"],"count":607,"armGroups":[{"label":"Trimethoprim-Sulfamethoxazole","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Trimethoprim-Sulfamethoxazole"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Trimethoprim-Sulfamethoxazole","otherNames":["Sulfatrim","Bactrim"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age at randomization: at least 2 months, but less than 6 years of age. Note that children as young as 1 month were screened for the study.\n* Diagnosed first or second febrile or symptomatic UTI within 112 days prior to randomization\n* Presence of Grade I- IV VUR based on radiographic voiding cystourethrogram (VCUG) performed within 112 days of diagnosis of index UTI.\n* Appropriately treated index febrile or symptomatic UTI\n\nExclusion Criteria:\n\n* Index UTI diagnosis more than 112 days prior to randomization\n* History of more than two UTIs prior to randomization\n* For patients less than 6 months of age at randomization, gestational age less than 34 weeks\n* Co-morbid urologic anomalies\n* Hydronephrosis, SFU Grade 4\n* Ureterocele\n* Urethral valve\n* Solitary kidney\n* Profoundly decreased renal size unilaterally on ultrasound (based on 2 standard deviations below the mean for age and length) performed within 112 days after diagnosis of index UTI\n* Multicystic dysplastic kidney\n* Neurogenic bladder\n* Pelvic kidney or fused kidney\n* Known sulfa allergy, inadequate renal or hepatic function, Glucose-6-phosphate dehydrogenase deficiency or other conditions that are contraindications for use of TMP-SMZ\n* History of other renal injury/disease\n* Unable to complete the study protocol\n* Congenital or acquired immunodeficiency\n* Underlying anomalies or chronic diseases that could potentially interfere with response to therapy such as chronic gastrointestinal conditions (i.e., malabsorption, inflammatory bowel disease), liver or kidney failure, or malignancy.\n* Complex cardiac disease as defined in the Manual of Procedures.\n* Any known syndromes associated with VUR or bladder dysfunction\n* Index UTI not successfully treated\n* Unlikely to complete follow-up\n* Family history of anaphylactic reaction to sulfa medications","healthyVolunteers":false,"sex":"ALL","minimumAge":"2 Months","maximumAge":"71 Months","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Recurrent Febrile or Symptomatic Urinary Tract Infection During 2-year Follow-up","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"72","spread":null}]}]}]},{"type":"SECONDARY","title":"Outcome Renal Scarring","description":"Renal scarring was defined as a decreased uptake of tracer that was associated with loss of contours or the presence of cortical thinning. Outcome dimercaptosuccinic acid (DMSA) scan was performed at 2 years after enrollment or 3-4 months after the child had met treatment failure criteria.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]}]},{"type":"SECONDARY","title":"Severe Renal Scarring on Outcome Scan","description":"Severe renal scarring was defined as scarring in more than 4 of 12 segments in at least one kidney or global atrophy characterized by diffusely scarred and shrunken kidney. Outcome DMSA scan performed at 2 years after enrollment or 3-4 months after the child had met treatment failure criteria.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"New Renal Scarring on Outcome Scan","description":"New renal scarring was defined as scarring on the outcome renal scan with technetium -99m-labeled dimercaptosuccinic acid that was not present at baseline. Outcome DMSA scan performed at 2 years after enrollment or 3-4 months after the child had met treatment failure criteria.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]}]},{"type":"SECONDARY","title":"Treatment Failure Composite","description":"Treatment failure was defined as the occurrence of two febrile urinary tract infections (UTIs), one febrile UTI and three symptomatic UTIs, four symptomatic UTIs, or new or worsening renal scarring on an interim scan (e.g,, the 12-month visit); renal scans from the 2-year visit are NOT considered in the treatment failure criteria.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"27","spread":null}]}]}]},{"type":"SECONDARY","title":"Presence of E.Coli Resistant to Trimethoprim-Sulfamethoxazole (TMP-SMZ) (Based on Rectal Swab)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"41","spread":null}]}]}]},{"type":"SECONDARY","title":"Recurrent Febrile or Symptomatic UTI With Resistant E. Coli","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]}]},{"type":"SECONDARY","title":"Recurrent Febrile or Symptomatic UTI With Any Resistant Pathogen","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":302},"commonTop":["Fever","Rash","Otitis Media","Pharyngitis","Viral Infection"]}}}